Patient-Reported Experiences during and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study

被引：2
|
作者：
Eliason, Laurie
Correll, Julia
Martin, Mona
Cardellino, Anna
Opalinska, Joanna
Piontek, Trisha
Gorsh, Boris
Sapra, Sandhya
Popat, Rakesh
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-139395
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Belantamab-mafodotin treatment for relapsed or refractory multiple myeloma
    Stocker, Nicolas
    HEMATOLOGIE, 2020, 26 (02): : 99 - 100
  • [42] METHODOLOGY FOR EVALUATING MEANINGFUL CHANGE THRESHOLDS IN PATIENT-REPORTED OUTCOME (PRO) MEASURES FOR CORNEAL EVENTS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) RECEIVING SINGLE-AGENT BELANTAMAB MAFODOTIN (BELAMAF)
    Eliason, L.
    Loubert, A.
    Gorsh, B.
    Meunier, J.
    Kleinman, D.
    Sapra, S.
    Regnault, A.
    VALUE IN HEALTH, 2020, 23 : S477 - S477
  • [43] DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor plus Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma
    Prawitz, Thibaud
    Popat, Rakesh
    Suvannasankha, Attaya
    Sarri, Grammati
    Hughes, Rachel
    Wang, Feng
    Hogea, Cosmina
    Ferrante, Shannon Allen
    Gorsh, Boris
    Willson, Jenny
    Kapetanakis, Venediktos
    ADVANCES IN THERAPY, 2021, 38 (11) : 5501 - 5518
  • [44] Belantamab Mafodotin, Pomalidomide, and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Patient-Reported Outcomes from DREAMM-8
    Dimopoulos, Meletios
    Beksac, Meral
    Pour, Ludek
    Delimpasi, Sosana
    Vorobyev, Vladimir
    Quach, Hang
    Spicka, Ivan
    Radocha, Jakub
    Robak, Pawel
    Kim, Kihyun
    Cavo, Michele
    Suzuki, Kazuhito
    Wilkes, Jodie
    Morris, Kristin
    Pompilus, Farrah
    Purser, Molly
    Philips-Jones, Amy
    Zhou, Xiaoou
    Fulci, Giulia
    Sule, Neal
    Kremer, Brandon
    Opalinska, Joanna
    Manteca, Maria-Victoria Mateos
    Trudel, Suzanne
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S9 - S9
  • [45] Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States
    Shah, Anshul
    Tosh, Jonathan C.
    Ambavane, Apoorva
    Nikolaou, Andreas
    Hogea, Cosmina
    Samyshkin, Yevgeniy
    Gorsh, Boris
    Maiese, Eric M.
    Wang, Feng
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 789 - 800
  • [46] Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)-related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM)
    Popat, Rakesh
    Kazantzi, Aikaterini
    Kleinman, David
    Lichenstein, Carolyn
    Paka, Prani
    Salter, John
    Byrne, Julie
    Doherty, Allison
    Degli Esposti, Simona
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S30 - S30
  • [47] Low-dose belantamab mafodotin (belamaf) in combination with nirogacestat vs belamaf monotherapy in patients with relapsed/refractory multiple myeloma (RRMM): phase I/II DREAMM-5 platform sub-study 3
    Leypoldt, L.
    Callander, N. S.
    Richardson, P. G.
    Hus, M.
    Ribrag, V.
    Lopez, J. M.
    Kim, K.
    Lee, J. H.
    Dimopoulos, M. A.
    Schjesvold, F.
    Facon, T.
    Jo, J. -C.
    Min, C. -K.
    Mielnik, M.
    Cheng, S.
    Smith, L. M.
    Breitbach, C. J.
    Brawley, C.
    Sembhi, H.
    LaMacchia, J.
    Grosicki, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 176 - 177
  • [48] Patient-Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Chari, Ajai
    Romanus, Dorothy
    DasMahapatra, Pronabesh
    Hoole, Michael
    Lowe, Maria
    Curran, Chris
    Campbell, Scott
    Bell, Jill A.
    ONCOLOGIST, 2019, 24 (11): : 1479 - 1487
  • [49] Real-world analysis of belantamab mafodotin (belamaf): Care patterns in relapsed/refractory multiple myeloma
    Patel, Mihir
    Locke, Susan C.
    Falvey, Caroline
    Troy, Jesse D.
    Herring, Kris W.
    Bolgioni-Smith, Amanda
    Doherty, Allison
    Elcock, Cherie Howard
    Iadeluca, Laura L.
    LeBlanc, Thomas William
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
    Nooka, Ajay K.
    Weisel, Katja
    van de Donk, Niels W. C. J.
    Routledge, David
    Otero, Paula Rodriguez
    Song, Kevin
    Quach, Hang
    Callander, Natalie
    Minnema, Monique C.
    Trudel, Suzanne
    Jackson, Nicola A.
    Ahlers, Christoph M.
    Im, Ellie
    Cheng, Shinta
    Smith, L.
    Hareth, Nahi
    Ferron-Brady, Geraldine
    Brouch, Maria
    de Oca, Rocio Montes
    Paul, Sofia
    Holkova, Beata
    Gupta, Ira
    Kremer, Brandon E.
    Richardson, Paul
    FUTURE ONCOLOGY, 2021, 17 (16) : 1987 - 2003
12345